Merck to deliver viral vector manufacturing services for Bluebird Bio

Merck has signed a new commercial supply agreement to manufacture viral vectors for the US-based life science company Bluebird Bio.

Under the terms of the multi-year agreement, Merck will manufacture lentiviral vectors for Bluebird Bio's drug products, which are being developed to treat a variety of rare genetic diseases.

Bluebird Bio is a clinical-stage company creating potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer.

This agreement will leverage Merck’s deep experience in producing viral vectors for gene therapy from clinical to commercial scale, and the capabilities of the firm's US-based manufacturing facility, which provides BioReliance viral and gene therapy manufacturing services.

Udit Batra, member of the executive board and chief executive officer for life science, said: "With 30 years' experience in viral vector manufacturing, we remain committed to innovating with academia, hospitals and cell therapy manufacturers to accelerate access to personalised cell therapy for the patients who need it most."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.